Vynfinit (vintafolide) / Novartis  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vynfinit (vintafolide) / Novartis
NCT01953536 / 2012-005170-65: Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)

Withdrawn
2a
0
US
Vintafolide 2.5 mg, Paclitaxel 80 mg/m^2, Etarfolatide, Folic acid, Premedication for Paclitaxel
Endocyte
Breast Neoplasms
11/16
11/16
NCT00507741: Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)

Checkmark In patients with advanced ovarian and endometrial cancers
Dec 2014 - Dec 2014: In patients with advanced ovarian and endometrial cancers
Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Checkmark P2 data vintafolide and companion SPECT-based imaging agent 99mTc-etarfolatide
More
Completed
2
49
US
Vintafolide, Ertafolide
Endocyte
Ovarian Cancer, Endometrial Cancer
04/09
04/09
NCT00511485: Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Completed
2
43
US
Vintafolide, Etarfolatide
Endocyte
Adenocarcinoma of the Lung
07/09
11/09
PRECEDENT, NCT00722592: Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)

Checkmark SGO 2014
Mar 2014 - Mar 2014: SGO 2014
Checkmark SGO 2014
Mar 2014 - Mar 2014: SGO 2014
Checkmark In pts with platinum-resistant ovarian cancer
More
Completed
2
162
US
Vintafolide, EC145, pegylated liposomal doxorubicin (PLD), Doxil®, Caelyx®, EC20, 99mTc-EC20
Endocyte
Ovarian Cancer
09/10
12/12
TARGET, NCT01577654 / 2012-000966-40: Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer

Checkmark From TARGET trial for NSCLC
Dec 2015 - Dec 2015: From TARGET trial for NSCLC
Checkmark Final OS data from TARGET trial in NSCLC
Sep 2015 - Sep 2015: Final OS data from TARGET trial in NSCLC
Checkmark Interim OS data from TARGET trial in NSCLC
More
Completed
2
203
NA
EC145, Vintafolide, EC145 + Docetaxel, Taxotere, Docetaxel, EC20, Etarfolatide
Endocyte
Non Small Cell Lung Cancer
12/13
08/15
NCT01002924: Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

Completed
2
1
US
EC145
Endocyte
Solid Tumors
12/13
12/13

Download Options